SNO bio’s mission is to create breakthrough medicines by exploiting the untapped biology of S-nitrosylation (SNO). Protein SNO is the human genome’s next major post-translational modification pathway drug discovery opportunity. Aberrant protein SNO alters protein function in many disease pathways. SNO bio’s platform identifies and prioritizes nitrosylase and denitrosylase regulating proteins as targets for our proprietary drug discovery engine.
Chris Larson is Co-Founder & Chief Executive Officer of SNO bio. Prior to starting SNO bio, Dr. Larson held scientific and scientific leadership positions in several biotech and pharmaceutical companies, including Ligand Pharmaceuticals, Deltagen Research Laboratories, Kemia, and Exelixis. Dr. Larson served as US Head & Associate Global Head of the Cardiovascular and Metabolic Diseases Drug Discovery Unit at Takeda Pharmaceuticals. Most recently, Dr. Larson held roles at the Sanford Burnham Prebys Medical Discovery Institute as Vice President for drug discovery, as Principal Investigator for his NIH funded laboratory studying cardiac diseases, and remains Adjunct Professor in the Graduate School of Biomedical Sciences. He had led numerous programs from initiation through IND, and contributed as a research scientist to three FDA-approved drugs.
Dr. Larson received a BA in chemistry from Carleton College and a PhD in chemistry from Harvard University. He completed a postdoctoral fellowship with Inder Verma at the Salk Institute for Biological Studies.
Jason O’Rourke is the Director of Pharmacology. Dr. O’Rourke previously held scientific positions at leading biotech companies. Most recently, he was Associate Director of Pharmacology at Fate Therapeutics. Prior to Fate Therapeutics, Dr. O’Rourke held several roles at Novartis and the Sanford Burnham Prebys Medical Discovery Institute.
Dr. O’Rourke earned a B.S. in microbiology at Ohio University, a Ph.D. in genetics at the University of Florida and completed postdoctoral training in Eric Olson’s lab at the UT Southwestern Medical Center.
John Stebbins is a Senior Scientist. Dr. Stebbins previously held various scientific positions. Most recently, he was a Research Scientist at Salimetrics, LLC. Prior to Salimetrics, Dr. Stebbins held several roles at the Sanford Burnham Prebys Medical Discovery Institute.
Dr. Stebbins earned a B.A. in biology at Carleton College, a Ph.D. in genetics at the Michigan State University and completed postdoctoral training in Lorraine Pillus’s lab at University of California San Diego.
Ian Pike oversees consulting for platform technologies at SNO bio by bringing focus to experimental design and date analysis to ensure maximum biological insights. Dr. Pike brings over thirty years of industrial research and senior management experience in the fields of proteomics and biomarkers. Dr. Pike is currently the Chief Scientific Officer at Proteome Sciences, PLC and sit on the board as Executive Director. He led the Tandem Mass Tag (TMT) technology and its licensing to Thermo Scientific. Dr. Pike has engaged with several academic startups in both technical and financial support aspects of business planning and financing, using his strengths in technology assessment and patent due diligence.
Dr. Pike obtained his PhD in Medical Microbiology and Bacteriology from the University of Leeds.
William Greenlee, in his capacity as consulting Head of Chemistry at SNO bio, brings more than three decades of experience in drug discovery and development. As the Founder and President of MedChem Discovery Consulting, LLC, he is also a Network Partner at Synergy Partners R&D Solutions. Dr. Greenlee was formerly the Senior Director of Chemistry at Merck Research Laboratories. Previously, he served as the Vice President of CNS & CV/MD Chemistry at Schering-Plough Research. He has provided leadership to research groups that have advanced more than 20 drug candidates to into preclinical development and 11 into clinical studies including Vasotec™ and Prinvil™. His previous focus discovery programs include cardiovascular/metabolic, and CNS therapy areas, infectious diseases and inflammation and programs.
Dr. Greenlee holds a BS in Chemistry from Ohio State University, his PhD in Organic Chemistry from Harvard University, and completed his postdoctoral work in Chemistry at Columbia University.
Ched Grimshaw in his capacity as consulting head of Biology for SNO bio, brings his extensive experience from Takeda California as the Director Enzymology group within the Biological Sciences Department. Dr. Grimshaw held roles as an Associate Director at Celgene and a Senior Scientist at Signal Pharmaceuticals. Previously, he conducted NIH funded research at the Scripps Research Institute, The Whittier Institute, and UCSD. Academically, he was an Associate Research Professor for the UCSD Department of Medicine. Dr. Grimshaw’s expertise in assay development, mechanistic enzymology and structure based drug design covers a broad range of target classes.
Dr. Grimshaw received his BS in Chemistry from the University of California at Berkeley, and his PhD in Biochemistry from the University of Wisconsin-Madison. He conducted his Postdoctoral work in Bioorganic Chemistry at Harvard University.
Jonathan S. Stamler, Co-Founder and Chair of the Scientific Advisory Board, is an internationally acclaimed physician scientist known for the discovery of protein S-nitrosylation, a global post-translational modification of proteins that is widely involved in both physiology and disease. He is currently a professor at Case Western University in the departments of Physiology and Biophysics and the President of Harrington Discovery Institute. Dr Stamle has a track record of innovation and entrepreneurship as a founder of institutes, biotechnology companies (9), medical societies, innovation platforms and impact investment funds. He has co-authored over 300 original manuscripts and 125 patents/patent applications, and has been recognized with multiple awards. His work has been covered in numerous lay publications, including the front page and science sections of the New York Times, as well as Time Magazine and The Economist, in books on the history of science and luck, and in works on outlier innovators.
Dr. Stamler obtained his Bachelor’s degree from Brandeis University, and earned his MD from Icahn School of Medicine at Mount Sinai. He conducted his residency and fellowship training in cardiovascular medicine at Brigham and Women’s Hospital at Harvard Medical School.
Harry Ischiropoulos, SNO bio scientific advisory board member, is the Gisela and Dennis Alter Research Professor of Pediatrics and Systems Pharmacology and Translational Therapeutics at the Children’s Hospital of Philadelphia Research Institute and the Perelman School of Medicine at the University of Pennsylvania. His laboratory investigates the biological chemistry and signaling pathways of nitric oxide in the cardiovascular and neuronal systems using mass spectroscopy-based technologies. Dr. Ischiropoulos has authored 195 publications and is the recipient of several professional awards including an Established Investigator award from the American Heart Association. He served on several NIH review panels and advisory committees. He was the President for the Society for Free Radical Biology and Medicine and served on the board of directors for the Federation of American Societies for Experimental Biology. He was an editor for the journal Free Radical Biology and Medicine and chaired the Gordon Research Conferences on Oxygen Radicals (2014) and on Nitric Oxide (2015).
Dr. Ischiropoulos received a B.S. in Chemistry from Wagner College, an M.S. in Pathology and a PhD in experimental pathology from New York Medical College.
Martin Seidel serves on the SNO bio Scientific Advisory Board and is CEO of IFM Therapeutics subsequent to his first role at IFM as Executive Vice President of Research and Development. Dr. Seidel previously held roles at Novartis, where he was the Global Head of Strategic Alliances (BD&L) for the Novartis Institutes for Biomedical Research (NIBR), Previously, he was head of NIBR’s Genomics Institute of the Novartis Research Foundation. In 11 years at GNF, he helped advance more than 40 clinical candidates, including 25 programs that progressed to the clinic, 13 new molecular entities that achieved positive clinical proof of concept and more than nine molecules that are now either FDA-approved drugs (Zykadia™/ceritinib, Odomzo®/sonedegib, Braftovi™/encorafenib, Mayzent® / siponimod) or in late-stage clinical development. He has served as Board Observer with IFM Therapeutics, Luc/Cadent Therapeutics, Surface Oncology, Raze Therapeutics, Arcus Biosciences, Intellia Therapeutics and Caribou Biosciences.
Dr. Seidel received his A.B.in Chemistry from Princeton University and earned his PhD in Chemistry from Harvard University.
Kenneth Morand, Board Member, is an executive-in-residence at CincyTech, who brings more than 25 years of R&D management and new business creation in life sciences & technology commercialization. He is the founder of StrategIn Consulting, LLC. Prior to CincyTech, Dr. Morand held various leadership roles with Procter & Gamble Company and Procter & Gamble Pharmaceuticals. He has extensive experience in biotechnology and drug development, strategic planning and business development, healthcare new business creation, and health/consumer technology development. Dr. Morand provides commercialization and technical mentoring as a member of the NIH Centers for Accelerated Innovations at the Cleveland Clinic, Cincinnati Children’s Hospital Commercialization Review Committee, University of Cincinnati Technology Accelerator Commercialization Committee, and the Ohio iCorp program sponsored by the NSF.
Kenny completed his BS degree in Chemistry at Rose-Hulman Institute of Technology, PhD in Analytical Chemistry at Purdue University, and Visiting Scholar Scientist at the European Molecular Biology Laboratory (EMBL) in Heidelberg.
